Webcast Alert: AtheroGenics Inc Announces Its Second Quarter 2006 Earnings Conference Call Webcast
19 Juillet 2006 - 2:30PM
Business Wire
AtheroGenics Inc (NASDAQ: AGIX) announces the following Webcast:
What: AtheroGenics Inc Second Quarter 2006 Earnings Conference Call
Webcast When: July 20, 2006 @ 09:00 AM Eastern Where:
http://www.investorcalendar.com/EventPage.asp?ID=106066 How: Live
over the Internet -- Simply log on to the web at the address above.
Contact: Donna Glasky, (678)336-2517 or dglasky@atherogenics.com If
you are unable to participate during the live webcast, the call
will be available for replay at
http://www.investorcalendar.com/ClientPage.asp?ID=106066 or
http://www.investorcalendar.com/ AtheroGenics is focused on the
discovery, development and commercialization of novel drugs for the
treatment of chronic inflammatory diseases, including heart disease
(atherosclerosis), rheumatoid arthritis and asthma. The Company has
two drug development programs currently in the clinic.
AtheroGenics' lead compound, AGI-1067, is being evaluated in the
pivotal Phase III ARISE clinical trial as an oral therapy for the
treatment of atherosclerosis, in collaboration with AstraZeneca.
AGI-1096 is a novel, oral agent in Phase I that is being developed
for the prevention of organ transplant rejection in collaboration
with Astellas. AtheroGenics also has preclinical programs in
rheumatoid arthritis and asthma utilizing its proprietary vascular
protectant(R) technology. For more information about AtheroGenics,
please visit www.atherogenics.com.
KraneShares Artificial I... (NASDAQ:AGIX)
Graphique Historique de l'Action
De Déc 2024 à Jan 2025
KraneShares Artificial I... (NASDAQ:AGIX)
Graphique Historique de l'Action
De Jan 2024 à Jan 2025
Real-Time news about KraneShares Artificial Intelligence ETF (NASDAQ): 0 recent articles
Plus d'articles sur AtheroGenics Inc